Get the Stockscreener App
0.3601
0.06%
-0.0002
Scienture Holdings Inc stock is traded at $0.3601, with a volume of 46,285.
It is down -0.06% in the last 24 hours and down -10.65% over the past month.
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on the commercialization and development of products for the treatment of cardiovascular (CVS) and Central Nervous System (CNS) diseases. Scienture LLC launched its first commercial product for hypertension and is in the process of commercializing its second product for the treatment of opioid overdose. Its development pipeline consists of a broad range of novel product candidates including new potential treatments for migraine, thrombosis, pain and other related disorders.
See More
Previous Close:
$0.3603
Open:
$0.3575
24h Volume:
46,285
Relative Volume:
0.07
Market Cap:
$14.63M
Revenue:
$656.60K
Net Income/Loss:
$-16.79M
P/E Ratio:
-0.3352
EPS:
-1.0743
Net Cash Flow:
$-11.12M
1W Performance:
-1.61%
1M Performance:
-10.65%
6M Performance:
-34.53%
1Y Performance:
-65.70%
1-Day Range:
$0.353
$0.3792
1-Week Range:
$0.34
$0.3979
52-Week Range:
$0.2382
$2.60
Scienture Holdings Inc Stock (SCNX) Company Profile
Name
Scienture Holdings Inc
Sector
Industry
Phone
(800) 261 0281
Address
20 AUSTIN BLVD., COMMACK
Compare SCNX vs HITI, PETS, POM, WGRX
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SCNX
Scienture Holdings Inc
|
0.3601 | 14.64M | 656.60K | -16.79M | -11.12M | -1.0743 |
HITI
High Tide Inc
|
2.535 | 197.77M | 452.61M | -35.30M | 13.25M | -0.3863 |
PETS
Petmed Express Inc
|
1.80 | 39.10M | 182.67M | -64.87M | -22.92M | -3.1193 |
POM
Pomdoctor Ltd Adr
|
0.0968 | 13.15M | 0 | 0 | 0 | 0.00 |
WGRX
Wellgistics Health Inc
|
3.65 | 9.40M | 14.03M | -76.59M | -13.73M | -41.45 |
Scienture Holdings Inc Stock (SCNX) Latest News
Exclusive: Scienture expands coverage for opioid overdose treatment ahead of commercial launch - MSN
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Boosts SentimentEarnings Weakness Phase - newsline.com
Scienture Holdings (SCNX) Investor Relations, Earnings Summary & Outlook - Quartr
Scienture Holdings Inc. (SCNX) Rallies 6.43% to $0.38, Nears Key ResistanceRSI Oversold Picks - newsline.com
Scienture Holdings Inc at Small Cap Showcase & WTR Insights Conference Transcript - GuruFocus
SCNX Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive MomentumCore Business Growth - newsline.com
Scienture’s naloxone nasal spray added to national health plan By Investing.com - Investing.com South Africa
Scienture Holdings, Inc. Secures Formulary Coverage for REZENOPYTM with Large National Health Plan and Expands Commercial Team - marketscreener.com
Scienture’s naloxone nasal spray added to national health plan - Investing.com UK
SCIENTURE Secures Formulary Coverage for REZENOPY™ with a Large National Health Plan and Expands Commercial Team - The Manila Times
EXCLUSIVE: Scienture Expands Coverage For Opioid Overdose Treatment Ahead Of Commercial Launch - Benzinga
Scienture Holdings (SCNX) Slides 5.26% as Stock Tests Key Support LevelsIchimoku TK Cross - newsline.com
SCIENTURE to Present at The Small Cap Showcase & WTR Insights on June 9, 2026, in NYC - Corsicana Daily Sun
Scienture (SCNX) Secures Patent for Rezenopy Nasal Spray - GuruFocus
Scienture Secures US Patent Protection for Rezenopy Through 2041 - marketscreener.com
Scienture receives patent for naloxone nasal spray until 2041 By Investing.com - Investing.com South Africa
Scienture receives patent for naloxone nasal spray until 2041 - Investing.com
SCIENTURE Receives U.S. Patent Covering REZENOPY™ (Naloxone HCl) Nasal Spray 10 mg, Strengthening Intellectual Property Protection Through 2041 - The Manila Times
New high-dose naloxone nasal spray wins U.S. patent to 2041 - Stock Titan
Scienture Holdings, Inc. (SCNX) 8-K Filing: Director Changes and Company Details for May 2026 - Minichart
Scienture Holdings Announces CFO Resignation, Names Interim Successor - The Globe and Mail
ScientureEric Sherb resigns as CFO effective May 26, 2026 - marketscreener.com
Scienture Holdings, Inc. Announces CFO Changes, Effective May 26, 2026 - marketscreener.com
SCNX Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise despite revenue absenceProfit Inflection Point - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Revenue AbsenceEarnings Preview - The Legal Advocate
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: EPS Surprise of 64% Narrows Loss Amid Strategic Progress - The Legal Advocate
SCNX Q1 2026 Earnings: Significant EPS Beat Despite Lack of RevenueNet Income Trends - Newser
Scienture Holdings Reports 449% Revenue Growth and 95.6% Gross Margin Expansion in Q1 2026, Driven by Arbli and REZENOPY Launches - Minichart
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Narrower-than-expected loss drives positive surprise - Newser
Scienture Holdings (SCNX) Faces Selling Pressure Near Key Support LevelViral Trade Signals - Newser
Scienture Holdings Inc. (SCNX) Q1 2026 Earnings: Significant EPS Beat Highlights Cost Discipline and Operational ProgressViral Trade Signals - Newser
Trxade Health announces name change to Scienture Holdings - Intellectia AI
MEDS Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
TRxADE Health, Inc. Announces Business Combination with Scienture, Inc., in a Transaction Valued at $103 Million - Intellectia AI
TRxADE Health, Inc. Announces Name Change to Scienture Holdings, Inc. - Intellectia AI
MEDS Stock: Price, Forecast, Financials & AI Analysis - Intellectia AI
MEDS News & Events - Intellectia AI
Scienture Holdings (SCNX) Q1 2026 Earnings Surprise: EPS $-0.08, Up SignificantViral Trade Signals - Newser
Scienture Holdings Releases Q1 2026 Financial Results - AlphaStreet
Scienture Holdings, Inc. released its financial results and business progress for the first quarter of 2026. - Bitget
Scienture Holdings Q1 revenue jumps on Arbli sales, operating expenses steady - TradingView
Scienture Holdings Inc Stock (SCNX) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.94%
2.14%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):